Literature DB >> 22939810

Resistant hypertension in visceral obesity.

Michał Holecki1, Jan Duława, Jerzy Chudek.   

Abstract

BACKGROUND: Visceral obesity increases the risk of arterial hypertension (78% of cases of hypertension in men and 65% of cases in women). The aim of the study is to assess the role of visceral obesity in causing resistant hypertension (RH).
METHODS: The survey was performed on 5065 hypertensive patients with visceral obesity. BP control was analyzed on the basis of office and home BP measurements. Patients reporting non-compliance were excluded from the study.
RESULTS: The percentage of RH after excluding undertreated patients (receiving less than 3 drugs or on at least 3-drug regimen without diuretic and without reaching target BP goal) was 13.9%. RH was more frequent only in obese with BMI ≥ 35 and <40 kg/m(2) (16.2%) and in morbidly obese individuals (26.5%). Patients with BMI ≥ 35 and <40 kg/m(2) and with morbid obesity were receiving three-drug therapy more frequently than patients with visceral obesity and BMI<30 kg/m(2). A multiple regression analysis revealed that obesity was associated with RH independent from longer than 5-year period of antihypertensive therapy, diabetes, smoking cigarettes, cardiovascular disease and heart failure. The analysis of home BP measurement revealed that in 11.1% of patients RH was in fact "white coat" hypertension.
CONCLUSIONS: Undertreatment, underuse of diuretics in multidrug regimens, and the "white-coat" effect are the most common reasons for over-diagnosing resistant hypertension in patients with visceral obesity. Obesity is an independent risk factor for the occurrence of RH.
Copyright © 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22939810     DOI: 10.1016/j.ejim.2012.04.012

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  12 in total

Review 1.  Renal sympathetic denervation: applications in hypertension and beyond.

Authors:  Michael Böhm; Dominik Linz; Daniel Urban; Felix Mahfoud; Christian Ukena
Journal:  Nat Rev Cardiol       Date:  2013-06-18       Impact factor: 32.419

2.  Leptin Activates Trpm7 Channels in the Carotid Body As a Mechanism of Obesity-Related Hypertension.

Authors:  Fang Zheng; Shengyu Mu; Nancy J Rusch
Journal:  Circ Res       Date:  2019-11-07       Impact factor: 17.367

3.  Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study.

Authors:  Nicholas Chiu; Julie C Lauffenburger; Jessica M Franklin; Niteesh K Choudhry
Journal:  Hypertens Res       Date:  2021-09-13       Impact factor: 3.872

Review 4.  Nonpharmacological Management of Resistant Hypertension.

Authors:  Ahmad Sabbahi; Richard Severin; Deepika Laddu; James E Sharman; Ross Arena; Cemal Ozemek
Journal:  Curr Cardiol Rep       Date:  2021-10-01       Impact factor: 3.955

Review 5.  Leptin as a Mediator of Obesity-Induced Hypertension.

Authors:  Balyssa B Bell; Kamal Rahmouni
Journal:  Curr Obes Rep       Date:  2016-12

6.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 7.  Renal sympathetic nervous system and the effects of denervation on renal arteries.

Authors:  Arun Kannan; Raul Ivan Medina; Nagapradeep Nagajothi; Saravanan Balamuthusamy
Journal:  World J Cardiol       Date:  2014-08-26

8.  Visceral fat reduction and increase of intracellular fluid in weight loss participants on antihypertension medication.

Authors:  Gerald C Dembrowski; Jessica W Barnes
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-07-16

9.  Long term trends in control of hypertension in the Northern Sweden MONICA study 1986-2009.

Authors:  Ellinor Törmä; Bo Carlberg; Marie Eriksson; Jan-Håkan Jansson; Mats Eliasson
Journal:  BMC Public Health       Date:  2015-09-24       Impact factor: 3.295

10.  Prevalence and clinical outcomes of patients with apparent treatment-resistant hypertension enrolled in Phase 2 cardiac rehabilitation.

Authors:  Luke J Laffin; Asad Khan; Katherine Lang; Erik H Van Iterson
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-23       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.